Open Access<p>PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve</p>
Author(s) -
Inger Haraldsson,
Li Gan,
Sara Svedlund,
Kristina Törngren,
Helena U. Westergren,
Björn Redfors,
Maria Lagerström-Fermér,
Oskar Angerås,
Truls Råmunddal,
Pétur Pétursson,
Jacob Odenstedt,
Per Albertsson,
David Erlinge,
Elmir Ömerovic
Publication year - 2019
Publication title -
vascular health and risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.892
H-Index - 68
eISSN - 1178-2048
pISSN - 1176-6344
DOI - 10.2147/vhrm.s209003
Subject(s) - medicine , coronary flow reserve , cardiology , mace , coronary artery disease , myocardial infarction , fractional flow reserve , angioplasty , prospective cohort study , angina , canadian cardiovascular society , percutaneous coronary intervention , coronary angiography
Survivors of myocardial infarction (MI) are at high risk of new major adverse cardiovascular events (MACE). Coronary flow reserve (CFR) is a strong and independent predictor of MACE. Understanding the prevalence of impaired CFR in this patient group and identifying risk markers for impaired CFR are important steps in the development of personalized and targeted treatment for high-risk individuals with prior MI.